Table 1.
Clinical characteristics of the study populations.
| N-AGT | DCM-NGT | DCM-AGT | |
|---|---|---|---|
| N | 5 | 5 | 5 |
| Age (year) | 62 ± 6 | 55 ± 3 | 60 ± 6 |
| Males/females (n) | 3/2 | 4/1 | 3/2 |
| Angina (n) | 5 | 2 | 1 |
| NYHA class II/III (n) | 1/0 | 3/2∗ | 3/2∗ |
| LV mass (g) | 175 ± 16 | 288 ± 27∗ | 292 ± 43∗ |
| LVEF (%) | 56 ± 2 | 34 ± 2∗ | 31 ± 1∗ |
| LVEDD (mm) | 51 ± 2 | 64 ± 2∗ | 66 ± 2∗ |
| BNP (pg/mL) | 20 ± 7 | 98 ± 22∗ | 104 ± 30∗ |
| NT-proBNP (pg/mL) | 128 ± 37 | 598 ± 130∗ | 604 ± 127∗ |
| Body mass index (kg/m2) | 28 ± 2 | 29 ± 2 | 30 ± 2 |
| Fasting insulin (pmol/L) | 77 ± 8 | 69 ± 9 | 84 ± 10 |
| Fasting glucose (mmol/L) | 5.6 ± 0.2 | 5.4 ± 0.2 | 5.8 ± 0.2 |
| OGTT 2 h glucose (mmol/L) | 10.8 ± 1.1 | 6.0 ± 0.6∗ | 10.9 ± 0.7§ |
| Triglycerides (mmol/L) | 0.66 ± 0.10 | 0.65 ± 0.19 | 1.14 ± 0.20§ |
| β-blockers (n) | 3 | 5 | 5 |
| ACE-inhibitors/AT-1 antagonists (n) | 4 | 5 | 5 |
| Antialdosteronic agents (n) | 0 | 3∗ | 4∗ |
| Furosemide ≥25 mg/die (n) | 1 | 5∗ | 5∗ |
LV mass: left ventricular mass; LVEF: left ventricular ejection fraction; LVEDD: left ventricular end diastolic diameter.
∗ p < 0.05 for the comparison with N-AGT.
§ p < 0.05 for the comparison between DCM-NGT and AGT.